Aldosterone as a Possible Contributor to Eye Diseases

Abstract Aldosterone, an effector molecule of the renin–angiotensin–aldosterone system (RAAS), has been receiving more attention in the field of ophthalmology because of its possible role in the pathogenesis of various eye diseases or abnormalities; it may even become a target for their treatment. P...

Full description

Saved in:
Bibliographic Details
Published in:Endocrinology (Philadelphia) 2022-12, Vol.164 (2)
Main Authors: Higashide, Tomomi, Hirooka, Kazuyuki, Kometani, Mitsuhiro, Sugiyama, Kazuhisa
Format: Article
Language:English
Subjects:
Abnormalities
Aldosterone
Angiotensin
Animal models
Animals
Central Serous Chorioretinopathy - complications
Diabetes mellitus
Diabetic Retinopathy - etiology
Edema
Endocrine disorders
Endocrinology
Eye
Eye diseases
Glaucoma
Glaucoma - complications
Macular Edema - complications
Mineralocorticoid receptors
Occlusion
Ophthalmology
Pathogenesis
Receptors
Receptors, Mineralocorticoid
Renin
Renin-Angiotensin System
Retina
Retinal Vein Occlusion - etiology
Retinopathy
Veins
Vision
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Aldosterone, an effector molecule of the renin–angiotensin–aldosterone system (RAAS), has been receiving more attention in the field of ophthalmology because of its possible role in the pathogenesis of various eye diseases or abnormalities; it may even become a target for their treatment. Primary aldosteronism, a typical model of a systemic aldosterone excess, may cause vision loss due to various ocular diseases, such as retinal vein occlusion, central serous chorioretinopathy, and, possibly glaucoma. RAAS components are present in various parts and types of cells present in the eye. Investigations of the local RAAS in various animal models of diabetic macular edema, retinal vein occlusion, retinopathy of prematurity, central serous chorioretinopathy, and glaucoma have found evidence that aldosterone or mineralocorticoid receptors may exacerbate the pathology of these disorders. Further studies are needed to elucidate whether the modulation of aldosterone or mineralocorticoid receptors is an effective treatment for preventing vision loss in patients with eye diseases.
ISSN:1945-7170
0013-7227
1945-7170
DOI:10.1210/endocr/bqac201